B
DGX icon

Bailard’s Quest Diagnostics DGX Stock Holding History

Bailard’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.2M Buy
5,681
+136
+2% +$26.7K 0.02% 319
2026
Q1 		$1.09M Buy
5,545
+1,499
+37% +$291K 0.03% 313
2025
Q4 		$702K Buy
+4,046
New +$737K 0.02% 401
2021
Q2 		– Sell
-2,668
Closed -$342K – 716
2021
Q1 		$342K Sell
2,668
-37,868
-93% -$4.67M 0.01% 472
2020
Q4 		$4.83M Buy
40,536
+378
+0.9% +$46.1K 0.22% 93
2020
Q3 		$4.6M Buy
40,158
+867
+2% +$102K 0.24% 84
2020
Q2 		$4.48M Buy
39,291
+3,995
+11% +$424K 0.25% 83
2020
Q1 		$2.83M Buy
35,296
+5,502
+18% +$570K 0.2% 100
2019
Q4 		$3.18M Buy
29,794
+7,520
+34% +$784K 0.18% 114
2019
Q3 		$2.38M Buy
22,274
+1,709
+8% +$175K 0.14% 139
2019
Q2 		$2.09M Buy
20,565
+882
+4% +$84.8K 0.13% 155
2019
Q1 		$1.77M Sell
19,683
-68
-0.3% -$5.89K 0.11% 165
2018
Q4 		$1.65M Sell
19,751
-14,664
-43% -$1.37M 0.11% 162
2018
Q3 		$3.71M Sell
34,415
-476
-1% -$52.2K 0.22% 101
2018
Q2 		$3.84M Buy
+34,891
New +$3.63M 0.23% 99

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Bailard's DGX Position: Q2 2026 in Review

Bailard increased its Quest Diagnostics (DGX) stake by 2.5% in Q2 2026, buying an estimated $26.7K and bringing the position to 5,681 shares worth $1.2M. The position accounts for 0.02% of the portfolio, ranked #319.

Bailard first reported a position in DGX in Q2 2018 and has held it in 15 quarters since. The position peaked at $4.83M in Q4 2020. 1,107 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Bailard held 5,681 shares of Quest Diagnostics worth $1.2M as of Q2 2026.
  • Bailard bought 136 Quest Diagnostics shares in Q2 2026, an estimated $26.7K.
  • Quest Diagnostics made up 0.02% of Bailard's portfolio in Q2 2026, its #319 holding.
  • Bailard first reported a position in Quest Diagnostics in Q2 2018 and has held it in 15 quarters since.
  • Bailard's Quest Diagnostics position peaked at $4.83M in Q4 2020.
  • 1,107 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.